Neurocrine Biosciences
NBIX
333 hedge funds and large institutions have $8.09B invested in Neurocrine Biosciences in 2019 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 121 increasing their positions, 107 reducing their positions, and 32 closing their positions.
103% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 32
13% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 107
10% more funds holding
Funds holding: 302 → 333 (+31)
8% more capital invested
Capital invested by funds: $7.51B → $8.09B (+$577M)
6% more call options, than puts
Call options by funds: $61.4M | Put options by funds: $58.1M
0.56% more ownership
Funds ownership: 97.46% → 98.02% (+0.56%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$313M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$49.5M |
| 3 |
CII
Capital International Inc
Los Angeles,
California
|
+$47.7M |
| 4 |
BlackRock
New York
|
+$25.9M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$19.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$102M |
| 2 |
HM
HealthCor Management
New York
|
-$82M |
| 3 |
Janus Henderson Group
London,
|
-$79.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$53.9M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$52M |
NBIX Hedge Fund Activity: Q3 2019 in Review
333 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2019, worth a combined $8.09B — up 7.7% from $7.51B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new NBIX positions and 32 closed out — a net gain of 33 holders — while 121 added to existing stakes and 107 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $313M. The largest seller was Point72 Asset Management, cutting an estimated $102M.
- 333 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2019, up from 302 in Q2 2019.
- Funds reported $8.09B of Neurocrine Biosciences stock for Q3 2019, up 7.7% quarter-over-quarter.
- 65 funds opened new Neurocrine Biosciences positions in Q3 2019 and 32 closed out, a net change of +33 holders.
- The largest Neurocrine Biosciences buyer in Q3 2019 was T. Rowe Price Associates, an estimated $313M added.
- The largest Neurocrine Biosciences seller in Q3 2019 was Point72 Asset Management, an estimated $102M sold.
Based on aggregated 13F filings for Q3 2019.